Ergoteles’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ergoteles’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,380	Closed	-$29.1K	–	942
2023 Q2	$29.1K	Buy	+1,380	New	+$42.5K	﹤0.01%	972

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's EIGR Position: Q3 2023 in Review

Ergoteles sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 1,380 shares — an estimated $29.1K sold.

Ergoteles first reported a position in EIGR in Q2 2023 and held it in 1 quarter. The position peaked at $29.1K in Q2 2023. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

Ergoteles reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 1,380 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $29.1K.
Ergoteles first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
Ergoteles's Eiger BioPharmaceuticals, Inc. position peaked at $29.1K in Q2 2023.
51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.